ArticleCureus2024
LGD-4033 and a Case of Drug-Induced Liver Injury: Exploring the Clinical Implications of Off-Label Selective Androgen Receptor Modulator Use in Healthy Adults.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selective androgen receptor modulators (SARMs), designed to treat conditions such as muscle wasting and osteoporosis, are widely used among healthy adults seeking muscle hypertrophy and enhanced athletic performance, despite a lack of Food and Drug Administration (FDA) approval. This trend may be driven by the misconception that SARMs are safer alternatives to anabolic steroids. However, SARMs such as LGD-4033 (Ligandrol) are associated with significant adverse effects, including hepatotoxicity, cardiovascular complications, endocrine disturbances, and psychiatric symptoms. This report examines the clinical implications of off-label SARM use, focusing on a case of drug-induced liver injury (DILI) in a 52-year-old male. The patient presented with pruritic jaundice, significant weight loss, and elevated liver enzymes following three months of high-dose LGD-4033 use. A diagnostic workup ruled out other potential causes of liver injury, implicating SARM use as the likely etiology. This case underscores the necessity for heightened clinical vigilance, early diagnosis, and prompt intervention to mitigate serious health outcomes associated with SARM misuse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.